Treatment of gastric cancer for survival-strategies in the USA and Japan

Lisa Baddi, Mary Mulcahy, Al Benson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.

Original languageEnglish (US)
Pages (from-to)15-30
Number of pages16
JournalAnnals of Cancer Research and Therapy
Issue number1-2
StatePublished - 2003


  • 5-FU
  • Adenocarcinoma
  • Bryostatin
  • Cis-platin
  • Docetaxel
  • Drug toxicity
  • G17DT
  • Gastric cancer
  • Irinotecan
  • LV5FU2
  • Marimastat
  • Phase II and III trials
  • Survival
  • V325

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of gastric cancer for survival-strategies in the USA and Japan'. Together they form a unique fingerprint.

Cite this